Screener
Eligibility screening
Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
1 US site in CA
Before we begin
Who are you filling this out for?
Your answer affects how the questions are phrased.
Screener
Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
1 US site in CA
Before we begin
Your answer affects how the questions are phrased.